Business Context and Reporting Period
This Form 8-K was filed by Hemispherx Biopharma, Inc. on January 10, 2013. The report addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements. The filing details the granting of year-end 2012 performance bonuses to the Senior Management Team by the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data disclosed relates to specific executive compensation awards:
- Dr. William Carter (Chairman, CEO, President & Chief Scientific Officer): $241,906 (25% of base compensation).
- Thomas Equels (Vice Chairman, Secretary & General Counsel): $129,500 (25% of base compensation).
- Dr. David Strayer (Medical Director and Chief Medical Officer): $68,008 (25% of base compensation).
- Charles Bernhardt (CFO & Chief Accounting Officer): $58,275 (25% of base compensation).
- Dr. R. Christopher Cavalli (Vice President of Quality Control): $37,351 (20% of base compensation).
Material Changes
The Compensation Committee noted that for the years 2009, 2010, and 2011, the company's Officer Compensation Expense relative to various Balance Sheet ratios was consistently lower than the average of its publicly-traded Peer Group. This historical context informed the decision to grant the 2012 bonuses.
Outlook, Risks, and Management Commentary
Management commentary indicates that bonus determinations were based on pre-established goals, including the continued productive interaction with the FDA concerning issues necessary for the approval of Ampligen(R) for Chronic Fatigue Syndrome. The filing does not contain specific forward-looking guidance, risk factors, or contingencies beyond the context of the FDA approval process.
Investor Verification Checklist
- Verify the total cash outflow impact of the disclosed bonuses on the company's liquidity position.
- Confirm the current status of the FDA review for Ampligen(R) for Chronic Fatigue Syndrome.
- Review the company's most recent 10-K or 10-Q to compare the disclosed officer compensation ratios against peer group averages.
- Check for any subsequent filings regarding the actual payment dates of these bonuses.